Theravance Biopharma TBPH Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's operating lease right-of-use asset amortization?
- Theravance Biopharma (TBPH) reported operating lease right-of-use asset amortization of $1.06M in Q1 2026.
- How has Theravance Biopharma's operating lease right-of-use asset amortization changed year-over-year?
- Theravance Biopharma's operating lease right-of-use asset amortization increased by 9.3% year-over-year, from $966K to $1.06M.
- What is the long-term trend for Theravance Biopharma's operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Theravance Biopharma's operating lease right-of-use asset amortization has grown at a 0.2% compound annual growth rate (CAGR), from $3.99M to $4.02M.